StocksMedium•10 November 2026•
1 min read
Harvard Bioscience Reports $0.06 GAAP EPS Loss in Q3 2026
Key Facts
1Harvard Bioscience reported a GAAP EPS loss of $0.06 for the quarter.
2The company's revenue reached $22.2 million for the reported period.
Harvard Bioscience reported a GAAP EPS loss of $0.06 for the third quarter of 2026. Seeking Alpha reported that the company's revenue reached $22.2 million for the reported period.
HBIO shares closed at $9.09 on November 9, 2026, with the session seeing a trading range between a low of $8.35 and a high of $9.32. These financial results come as the company manages its operational performance within the healthcare equipment sector.